Athira Pharma (ATHA) Competitors $0.40 +0.00 (+0.91%) Closing price 04:00 PM EasternExtended Trading$0.39 -0.01 (-2.01%) As of 04:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ATHA vs. IZTC, APLT, ICCC, IMA, VRCA, DRRX, BMEA, ANL, CGTX, and BRNSShould you be buying Athira Pharma stock or one of its competitors? The main competitors of Athira Pharma include Invizyne Technologies (IZTC), Applied Therapeutics (APLT), ImmuCell (ICCC), ImageneBio (IMA), Verrica Pharmaceuticals (VRCA), DURECT (DRRX), Biomea Fusion (BMEA), Adlai Nortye (ANL), Cognition Therapeutics (CGTX), and Barinthus Biotherapeutics (BRNS). These companies are all part of the "pharmaceutical products" industry. Athira Pharma vs. Its Competitors Invizyne Technologies Applied Therapeutics ImmuCell ImageneBio Verrica Pharmaceuticals DURECT Biomea Fusion Adlai Nortye Cognition Therapeutics Barinthus Biotherapeutics Athira Pharma (NASDAQ:ATHA) and Invizyne Technologies (NASDAQ:IZTC) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, profitability, institutional ownership, media sentiment, valuation, earnings and analyst recommendations. Does the media favor ATHA or IZTC? In the previous week, Invizyne Technologies had 1 more articles in the media than Athira Pharma. MarketBeat recorded 1 mentions for Invizyne Technologies and 0 mentions for Athira Pharma. Athira Pharma's average media sentiment score of 1.87 beat Invizyne Technologies' score of 0.00 indicating that Athira Pharma is being referred to more favorably in the media. Company Overall Sentiment Athira Pharma Very Positive Invizyne Technologies Neutral Is ATHA or IZTC more profitable? Invizyne Technologies' return on equity of 0.00% beat Athira Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Athira PharmaN/A -139.40% -106.84% Invizyne Technologies N/A N/A N/A Which has better earnings & valuation, ATHA or IZTC? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAthira PharmaN/AN/A-$96.94M-$1.55-0.26Invizyne TechnologiesN/AN/AN/AN/AN/A Do insiders & institutionals believe in ATHA or IZTC? 57.1% of Athira Pharma shares are owned by institutional investors. 22.1% of Athira Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Do analysts recommend ATHA or IZTC? Athira Pharma presently has a consensus price target of $0.50, indicating a potential upside of 25.63%. Given Athira Pharma's stronger consensus rating and higher possible upside, equities research analysts plainly believe Athira Pharma is more favorable than Invizyne Technologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Athira Pharma 0 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Invizyne Technologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryAthira Pharma beats Invizyne Technologies on 5 of the 8 factors compared between the two stocks. Get Athira Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ATHA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ATHA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATHA vs. The Competition Export to ExcelMetricAthira PharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$15.70M$3.09B$5.82B$9.74BDividend YieldN/A2.23%3.84%4.09%P/E Ratio-0.2621.1431.1525.97Price / SalesN/A399.83475.57123.18Price / CashN/A43.0937.1558.38Price / Book0.498.079.116.39Net Income-$96.94M-$54.72M$3.26B$265.66M7 Day Performance-0.67%2.62%2.11%1.98%1 Month Performance-14.81%7.63%5.12%1.33%1 Year Performance-87.20%13.11%31.25%21.15% Athira Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATHAAthira Pharma3.821 of 5 stars$0.40+0.9%$0.50+25.6%-88.1%$15.70MN/A-0.2640News CoverageIZTCInvizyne TechnologiesN/A$9.84-1.7%N/AN/A$61.52MN/A0.0029News CoverageGap DownAPLTApplied Therapeutics4.2796 of 5 stars$0.45+5.5%$6.10+1,258.3%-91.7%$60.26M$460K-1.0430News CoveragePositive NewsShort Interest ↓Analyst RevisionICCCImmuCell0.6308 of 5 stars$6.66flatN/A+62.5%$60.19M$26.49M-95.1370News CoverageShort Interest ↓IMAImageneBio2.5884 of 5 stars$14.74+0.5%$35.50+140.8%-32.2%$58.97M$9.16M-1.9270VRCAVerrica Pharmaceuticals4.5953 of 5 stars$6.70+5.5%$80.00+1,094.0%-80.3%$58.73M$7.57M-0.5640Positive NewsShort Interest ↓DRRXDURECT2.2979 of 5 stars$1.87flatN/A+42.3%$58.05M$2.03M-12.4780Positive NewsBMEABiomea Fusion3.5124 of 5 stars$1.53-0.6%$16.80+998.0%-71.4%$57.86MN/A-0.5050ANLAdlai Nortye1.4372 of 5 stars$1.61+3.2%$9.00+459.0%-43.7%$57.56M$5M0.00127Positive NewsGap DownCGTXCognition Therapeutics1.7413 of 5 stars$0.86+13.8%$2.83+230.0%+165.4%$55.44MN/A-1.2820Short Interest ↓BRNSBarinthus Biotherapeutics2.9281 of 5 stars$1.14-14.9%$6.25+448.2%-6.7%$54.06M$14.97M-0.66107Negative NewsShort Interest ↑ Related Companies and Tools Related Companies IZTC Competitors APLT Competitors ICCC Competitors IMA Competitors VRCA Competitors DRRX Competitors BMEA Competitors ANL Competitors CGTX Competitors BRNS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ATHA) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredThe stealth altcoin the financial world is underestimatingThis DeFi project could soar next When altcoin season fully kicks in—which the data suggests is happening R...Crypto 101 Media | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredA grave, grave error.Nvidia just shattered records—hitting $4 trillion in valuation faster than any company in history. But one ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Athira Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Athira Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access